# Medicine Research.CRO

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/medicine-research-cro

- Industry: Pharmaceuticals
- Headquarters: Beijing, China
- Website: www.ccmts.com.cn
- Latest round: Series A (Mar 19, 2025)
- Investors on record: 2

## About

Medicine Research.CRO is a Beijing-based Contract Research Organization specializing in pharmaceutical and healthcare technical services, focusing on drug research, clinical trial support, and regulatory compliance for clients worldwide.Founded in 2018, Medicine Research.CRO operates as a Contract Research Organization providing essential services for pharmaceutical development. The company has engaged in two significant deals, with its most recent deal taking place on March 19, 2025. It has not publicly acknowledged any significant pivots in business strategy or operations, nor has it indicated any parent or subsidiary relationships. Details regarding the founder's history and previous ventures are not publicly available.Beijing Huayao Kechuan Pharmaceutical Technology Development Co., Ltd. specializes in a diverse range of services and solutions within the pharmaceutical and healthcare sectors. The company offers a comprehensive suite of Contract Research Organization (CRO) technical services, which include drug research, clinical trial support, and biobank testing services. These services aim to facilitate pharmaceutical development, enhance drug efficacy, and ensure compliance with regulatory standards, thereby addressing the needs of pharmaceutical companies and research institutions. Additionally, the firm provides registration consultation and Market Authorization Holder (MAH) services, which support clients in navigating the complex landscape of drug and medical device approvals in various international markets, including Europe and North America. The target clientele comprises pharmaceutical manufacturers, biotech firms, and healthcare organizations seeking to streamline their product development processes and improve market access.Revenue generation for Beijing Huayao Kechuan is primarily driven by a B2B service model, where the company engages directly with pharmaceutical companies and research institutions. The firm’s transactional structure includes fixed-price contracts for specific research projects, subscription-based models for ongoing CRO services, and consulting fees for regulatory guidance. Each engagement typically involves detailed service agreements tailored to the specific needs of clients, ensuring a clear understanding of deliverables and timelines. The company’s flagship offerings, which include high-end formulation development and clinical trial management, are integral to its service portfolio, providing clients with a robust framework for advancing their pharmaceutical innovations. Revenue is predominantly derived from these long-term partnerships, which foster repeat business and establish a solid foundation for future growth.In March 2025, Medicine Research.CRO raised an undisclosed amount of Series A+ funding from new investors Sinar Mas & Zijin Venture Capital Management, which will be directed towards developing new pharmaceutical products and expanding market reach. The company plans to introduce innovative solutions to enhance its CRO offerings by mid-2026. Furthermore, it aims to penetrate additional international markets, specifically targeting regions in Europe and North America, by the end of 2026. This strategic expansion is anticipated to augment its capacity to serve an increasing clientele in the pharmaceutical sector.

## Funding rounds

- Series A, Mar 19, 2025 — Sinar Mas & Zijin Venture Capital Management
- Series A, Dec 12, 2024 — Henan Guokong Fund Management

## Investors

- Henan Guokong Fund Management (https://capitalatlas.ai/funds/henan-guokong-fund-management) — Series A
- Sinar Mas & Zijin Venture Capital Management (https://capitalatlas.ai/funds/sinar-mas-zijin-venture-capital-management) — Series A